-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 24th National Conference on Clinical Oncology and the 2021 CSCO Annual Conference will be held on September 25-29, 2021.
The theme of this conference is "Focus on Innovative Research, Leading the Original Future"
.
The conference continues to adhere to the fundamental purpose of CSCO, adopts new forms to actively carry out academic exchange activities in special periods, promotes academic exchanges and scientific and technological cooperation in the field of clinical oncology in China, encourages support for clinical research and innovation, and advocates multidisciplinary standardized comprehensive treatment based on Precision oncology actively promotes the development of the discipline
.
At the CSCO conference, Professor Xu Wei from the First Affiliated Hospital of Nanjing Medical University gave a theme report on "Research Progress in Chronic Lymphocytic Leukemia (CLL)".
Yimaitong organized the main contents as follows
.
Research progress related to the prognosis of CLL patients Professor Xu Wei first introduced the research progress related to the prognosis of CLL
.
This year’s EHA conference announced the results of a study exploring the impact of CLL mutant genes on clinical prognosis
.
The results of this study of 4764 patients showed that 36.
8% (1720 cases) of CLL patients contained gene mutations of BIRC3, EGR2, NFKBIE, MYD88, NOTCH1, POT1, SF3B1, TP53, and XPO1, and 28.
0% (1301 cases) of CLL The patient only has a mutation in one of the 9 genes mentioned above
.
Univariate analysis showed that in addition to the MYD88 gene mutation, the other 8 gene mutations were associated with the shortening of the time to first treatment (TTFT)
.
This year’s EHA conference also announced a study on the incidence of second primary malignancies (SPM) in CLL patients in the Netherlands.
.
The study included 23,622 patients with CLL, of which 61% were men, with a median age of 69 years
.
At a median follow-up of 4 years, SPM occurred in 4062 patients (17%)
.
Compared with the general population, the risk of SPM in CLL patients is 66% higher, and the risk of SPM in CLL patients aged 18-60 is higher than that in CLL patients ≥60 years old
.
The research progress of initial treatment of CLL Professor Xu Wei then introduced the research progress of initial treatment of CLL
.
The Phase III RESONATE-2 study compared the efficacy of the BTK inhibitor ibrutinib and chlorambucil in the first-line treatment of CLL patients
.
The study’s recently announced long-term follow-up results showed that at a median follow-up of 6.
5 years, the overall survival (OS) rate of patients in the ibrutinib group reached 78%, the median progression-free survival (PFS) did not reach, and the overall response rate ( ORR) reached 92%, and the complete remission (CR)/complete remission (CRi) rate with incomplete hematological recovery reached 34%
.
Ibrutinib has shown a good long-term effect in this study and is a better first-line treatment option for CLL patients
.
The Phase II CAPTIVATE study explored the efficacy of a fixed course of Ibrutinib combined with the Bcl-2 inhibitor Venecla regimen in the treatment of CLL
.
The results of the study announced at the ASCO conference this year showed that at a median follow-up time of 27.
9 months (range: 0.
8-33.
2), patients who received a fixed course of ibrutinib combined with venacral had an ORR of 96% and a CR rate of 55.
% (95%CI: 48%-63%)
.
Among 88 patients who got CR, 78 (89%) patients got permanent CR (duration ≥ 1 year)
.
The 24-month PFS rate of the fixed course of treatment was 95%, and the 24-month OS rate was 98%
.
77% of patients had peripheral blood (PB) minimal residual disease (MRD) negative status, and 60% of patients had bone marrow (BM) MRD negative status
.
In addition, the curative benefits of a fixed course of treatment are not affected by prognostic factors such as del(17p) and TP53 mutations
.
The Phase III GLOW study also explored the efficacy of a fixed course of Ibrutinib combined with Venecla in the first-line treatment of CLL
.
The study included elderly (≥65 years of age) CLL patients who were randomly assigned to receive 12 cycles of Ibrutinib combined with Venecla or otuzumab combined with chlorambucil
.
The results of the study announced at this year’s EHA conference showed that at a median follow-up of 27.
7 months, patients in the ibrutinib combined with Venecla group had longer PFS (median PFS: less than 21.
0 months), and the CR/CRi rate was significant Higher (38.
7% vs 11.
4%; P<0.
0001), the negative rate of PB MRD (54.
7% vs 39.
0%) and the negative rate of BM MRD (51.
9% vs 17.
1%) at 3 months after the end of treatment were also higher
.
A fixed course of Ibrutinib combined with Venecla may bring better clinical benefits to newly treated CLL patients, and its treatment prospects are worthy of attention
.
The progress of the treatment of relapsed and refractory CLL Professor Xu Wei then introduced the research progress of relapsed and refractory (R/R) CLL
.
Chimeric antigen receptor T cell (CAR-T) immunotherapy is a new type of therapy that has attracted much attention in the field of hematological tumors in recent years.
The Phase I/II TRANSCEND CLL 004 study explored the CD19 CAR-T therapy Lisocabtagene Maraleucel (liso-cel) Efficacy of combined ibrutinib in patients with R/R CLL
.
The results of the study showed that the ORR of liso-cel combined with ibrutinib in the treatment of R/R CLL reached 95%, and the CR/Cri rate reached 47%
.
The prospect of CAR-T therapy in R/R CLL is worth looking forward to
.
The therapeutic prospects of the highly selective, non-covalently bound BTK inhibitor LOXO-305 in R/R CLL are also worthy of attention
.
The results of the Phase I/II BRUIN study showed that at a median follow-up of 6 months, the ORR of patients with R/R CLL treated with LOXO-305 reached 63%
.
For R/R CLL patients who have failed previous BTK inhibitor therapy, the ORR of LOXO-305 still reached 62%
.
For R/R CLL patients who have failed previous BTK inhibitor treatment, LOXO-305 is expected to provide a new treatment option
.
Summary Professor Xu Wei finally concluded: The long-term follow-up results of the Phase III RESONATE-2 study confirmed the long-term benefits of Ibrutinib for newly treated CLL patients
.
The fixed course of treatment has shown a good initial effect in the initial treatment of CLL, and its application prospects are worthy of attention
.
The combination of immunotherapy and targeted drugs has shown excellent efficacy in patients with R/R CLL.
We look forward to the long-term follow-up results of related studies in the future, which will provide more guidance for the treatment strategy of R/R CLL
.
Professor Wei Xu, Chief Physician, and PhD Supervisor Deputy Director of the Department of Hematology, First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) Deputy Chairman of the Hematology Oncology Committee of the Chinese Anti-Cancer Association, Leader of the Lymphoma Group, China Association for Geriatric Health Care Lymphoma Professional Committee Vice Chairman CSCO China Anti-Lymphoma Alliance Standing Committee Member of the Standing Committee of the Chinese Society of Geriatrics Hematology Branch Member of the Standing Committee of the Chinese Women Physicians Association Standing Committee of the Hematology Professional Committee of the Chinese Society of Geriatric Oncology Member of the Professional Committee of Experimental Hematology of the Society of Pathophysiology Member and Secretary of the Professional Committee of Integrative Hematology of the Chinese Medical Physician Association Chairman of the Lymphoma Alliance, Vice Chairman of the Hematological Oncology Committee of Jiangsu Anti-Cancer Association, Member of the Standing Committee of the Lymphoma Professional Committee of Jiangsu Anti-Cancer Association, Vice Chairman of Nanjing Society of Hematology, Chinese Journal of Hematology, Chinese Journal of Experimental Hematology, and International Journal of Blood Transfusion and Hematology, "Leukemia·Lymphoma" and "BLOOD Chinese Edition" and other journals stamp "read the original text", we make progress together
The theme of this conference is "Focus on Innovative Research, Leading the Original Future"
.
The conference continues to adhere to the fundamental purpose of CSCO, adopts new forms to actively carry out academic exchange activities in special periods, promotes academic exchanges and scientific and technological cooperation in the field of clinical oncology in China, encourages support for clinical research and innovation, and advocates multidisciplinary standardized comprehensive treatment based on Precision oncology actively promotes the development of the discipline
.
At the CSCO conference, Professor Xu Wei from the First Affiliated Hospital of Nanjing Medical University gave a theme report on "Research Progress in Chronic Lymphocytic Leukemia (CLL)".
Yimaitong organized the main contents as follows
.
Research progress related to the prognosis of CLL patients Professor Xu Wei first introduced the research progress related to the prognosis of CLL
.
This year’s EHA conference announced the results of a study exploring the impact of CLL mutant genes on clinical prognosis
.
The results of this study of 4764 patients showed that 36.
8% (1720 cases) of CLL patients contained gene mutations of BIRC3, EGR2, NFKBIE, MYD88, NOTCH1, POT1, SF3B1, TP53, and XPO1, and 28.
0% (1301 cases) of CLL The patient only has a mutation in one of the 9 genes mentioned above
.
Univariate analysis showed that in addition to the MYD88 gene mutation, the other 8 gene mutations were associated with the shortening of the time to first treatment (TTFT)
.
This year’s EHA conference also announced a study on the incidence of second primary malignancies (SPM) in CLL patients in the Netherlands.
.
The study included 23,622 patients with CLL, of which 61% were men, with a median age of 69 years
.
At a median follow-up of 4 years, SPM occurred in 4062 patients (17%)
.
Compared with the general population, the risk of SPM in CLL patients is 66% higher, and the risk of SPM in CLL patients aged 18-60 is higher than that in CLL patients ≥60 years old
.
The research progress of initial treatment of CLL Professor Xu Wei then introduced the research progress of initial treatment of CLL
.
The Phase III RESONATE-2 study compared the efficacy of the BTK inhibitor ibrutinib and chlorambucil in the first-line treatment of CLL patients
.
The study’s recently announced long-term follow-up results showed that at a median follow-up of 6.
5 years, the overall survival (OS) rate of patients in the ibrutinib group reached 78%, the median progression-free survival (PFS) did not reach, and the overall response rate ( ORR) reached 92%, and the complete remission (CR)/complete remission (CRi) rate with incomplete hematological recovery reached 34%
.
Ibrutinib has shown a good long-term effect in this study and is a better first-line treatment option for CLL patients
.
The Phase II CAPTIVATE study explored the efficacy of a fixed course of Ibrutinib combined with the Bcl-2 inhibitor Venecla regimen in the treatment of CLL
.
The results of the study announced at the ASCO conference this year showed that at a median follow-up time of 27.
9 months (range: 0.
8-33.
2), patients who received a fixed course of ibrutinib combined with venacral had an ORR of 96% and a CR rate of 55.
% (95%CI: 48%-63%)
.
Among 88 patients who got CR, 78 (89%) patients got permanent CR (duration ≥ 1 year)
.
The 24-month PFS rate of the fixed course of treatment was 95%, and the 24-month OS rate was 98%
.
77% of patients had peripheral blood (PB) minimal residual disease (MRD) negative status, and 60% of patients had bone marrow (BM) MRD negative status
.
In addition, the curative benefits of a fixed course of treatment are not affected by prognostic factors such as del(17p) and TP53 mutations
.
The Phase III GLOW study also explored the efficacy of a fixed course of Ibrutinib combined with Venecla in the first-line treatment of CLL
.
The study included elderly (≥65 years of age) CLL patients who were randomly assigned to receive 12 cycles of Ibrutinib combined with Venecla or otuzumab combined with chlorambucil
.
The results of the study announced at this year’s EHA conference showed that at a median follow-up of 27.
7 months, patients in the ibrutinib combined with Venecla group had longer PFS (median PFS: less than 21.
0 months), and the CR/CRi rate was significant Higher (38.
7% vs 11.
4%; P<0.
0001), the negative rate of PB MRD (54.
7% vs 39.
0%) and the negative rate of BM MRD (51.
9% vs 17.
1%) at 3 months after the end of treatment were also higher
.
A fixed course of Ibrutinib combined with Venecla may bring better clinical benefits to newly treated CLL patients, and its treatment prospects are worthy of attention
.
The progress of the treatment of relapsed and refractory CLL Professor Xu Wei then introduced the research progress of relapsed and refractory (R/R) CLL
.
Chimeric antigen receptor T cell (CAR-T) immunotherapy is a new type of therapy that has attracted much attention in the field of hematological tumors in recent years.
The Phase I/II TRANSCEND CLL 004 study explored the CD19 CAR-T therapy Lisocabtagene Maraleucel (liso-cel) Efficacy of combined ibrutinib in patients with R/R CLL
.
The results of the study showed that the ORR of liso-cel combined with ibrutinib in the treatment of R/R CLL reached 95%, and the CR/Cri rate reached 47%
.
The prospect of CAR-T therapy in R/R CLL is worth looking forward to
.
The therapeutic prospects of the highly selective, non-covalently bound BTK inhibitor LOXO-305 in R/R CLL are also worthy of attention
.
The results of the Phase I/II BRUIN study showed that at a median follow-up of 6 months, the ORR of patients with R/R CLL treated with LOXO-305 reached 63%
.
For R/R CLL patients who have failed previous BTK inhibitor therapy, the ORR of LOXO-305 still reached 62%
.
For R/R CLL patients who have failed previous BTK inhibitor treatment, LOXO-305 is expected to provide a new treatment option
.
Summary Professor Xu Wei finally concluded: The long-term follow-up results of the Phase III RESONATE-2 study confirmed the long-term benefits of Ibrutinib for newly treated CLL patients
.
The fixed course of treatment has shown a good initial effect in the initial treatment of CLL, and its application prospects are worthy of attention
.
The combination of immunotherapy and targeted drugs has shown excellent efficacy in patients with R/R CLL.
We look forward to the long-term follow-up results of related studies in the future, which will provide more guidance for the treatment strategy of R/R CLL
.
Professor Wei Xu, Chief Physician, and PhD Supervisor Deputy Director of the Department of Hematology, First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) Deputy Chairman of the Hematology Oncology Committee of the Chinese Anti-Cancer Association, Leader of the Lymphoma Group, China Association for Geriatric Health Care Lymphoma Professional Committee Vice Chairman CSCO China Anti-Lymphoma Alliance Standing Committee Member of the Standing Committee of the Chinese Society of Geriatrics Hematology Branch Member of the Standing Committee of the Chinese Women Physicians Association Standing Committee of the Hematology Professional Committee of the Chinese Society of Geriatric Oncology Member of the Professional Committee of Experimental Hematology of the Society of Pathophysiology Member and Secretary of the Professional Committee of Integrative Hematology of the Chinese Medical Physician Association Chairman of the Lymphoma Alliance, Vice Chairman of the Hematological Oncology Committee of Jiangsu Anti-Cancer Association, Member of the Standing Committee of the Lymphoma Professional Committee of Jiangsu Anti-Cancer Association, Vice Chairman of Nanjing Society of Hematology, Chinese Journal of Hematology, Chinese Journal of Experimental Hematology, and International Journal of Blood Transfusion and Hematology, "Leukemia·Lymphoma" and "BLOOD Chinese Edition" and other journals stamp "read the original text", we make progress together
